濮阳东方看男科病收费比较低濮阳东方男科口碑好服务好,濮阳东方医院妇科做人流价格收费低,濮阳东方妇科医院技术很专业,濮阳东方医院割包皮费用,濮阳东方医院非常好,濮阳东方医院妇科很正规,濮阳东方口碑高不高

WASHINGTON, Dec. 5 (Xinhua) -- A recent study found that low vitamin D levels are significantly more prevalent in obese children and are associated with risk factors for type 2 diabetes. This study was accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism.High rates of vitamin D deficiency have been found in obese populations and past studies have linked low vitamin D levels to cardiovascular disease and type 2 diabetes. But the mechanisms by which obesity and its comorbidities are related to vitamin D deficiency are not fully known.This new study examined associations between vitamin D levels and dietary habits in obese children, and tested whether there were correlations between vitamin D levels and markers of abnormal glucose metabolism and blood pressure.In this study, researchers measured vitamin D levels, blood sugar levels, serum insulin, body mass index (BMI) and blood pressure in 411 obese subjects and 87 control non-overweight subjects. Study participants were also asked to provide dietary information including daily intake of soda, juice and milk, average daily fruit and vegetable intake, and whether or not they routinely skipped breakfast. BMI is a measurement of body fat calculated from weight and height."Our study found that obese children with lower vitamin D levels had higher degrees of insulin resistance," said Micah Olson, of The University of Texas Southwestern Medical Center in Dallas and lead author of the study. "Although our study cannot prove causation, it does suggest that low vitamin D levels may play a role in the development of type 2 diabetes.""Poor dietary habits such as skipping breakfast and increased soda and juice intake were associated with the lower vitamin D levels seen in obese children," said Olson. "Future studies are needed to determine the clinical significance of lower vitamin D levels in obese children ... and whether treatment with vitamin D can improve primary clinical endpoints such as insulin resistance. "

ACCRA, Dec. 1 (Xinhua) -- The Ghanaian government allayed the fears of many here on Thursday that it would provide funding for the treatment of persons living with HIV/AIDS in the country.Vice President John Dramani Mahama affirmed this when he addressed a ceremony to mark this year's World AIDS Day at Obuasi, near Kumasi, 270 km north of the capital Accra.Mahama said should the Global Fund pull out of supporting the country, the government would partner with development partners to raise the 5.8 million U. S. dollars needed yearly for the treatment of HIV/AIDS patients."Government will work together with the Ghana AIDS Commission (GAC) and donor partners to ensure that people living with HIV/ AIDS have access to antiretroviral drugs."The Presidency is with you, and whatever we will do to win the fight against HIV/AIDS shall be done," Mahama said.Ghana's HIV/AIDS infection rate, according to official figures, has dropped from 3 percent to the current 1.5 percent, albeit with pockets of higher rates of infection among some populations in the country.Mahama called for more innovativeness in mobilizing resources to avoid the danger of retrogression.Director-General of the GAC Angela El-Adas announced that the Ministry of Health had pledged 2.5 million Ghana cedis (1.66 million dollars) out of the 5.8 million dollars needed for next year.Meanwhile, in the capital, the Ghana Network of Persons Living with HIV and AIDS (NAP+ GHANA) joined persons living with HIV (PLHIV) globally on Thursday to commemorate this year's World AIDS Day."We stand united with our fellow PLHIV and the global HIV and AIDS community by fully supporting the vision of 'Getting to Zero', " Charity Owusu Danso, vice president of NAP+ Ghana, said in a message here.Established in 2005, NAP+GHANA is a network of member associations of persons living with HIV/AIDS in Ghana to represent the views, hopes and aspirations of PLHIV across the country."We are extremely worried. Everyday, we receive reports from PLHIV across the country that anti-retroviral drugs are out of stock or that hospitals or clinics won't give HIV treatment to new patients because there aren't even enough drugs for existing patients, " the statement said.

LOS ANGELES, Oct. 3 (Xinhua) -- An organizer of the World Stem Cell Summit says one of the key problems medical researchers face these days is how to apply their findings in the real world."How do you take the phenomenal scientific research going on in labs and translate it into medical treatments,?" said Bernie Siegel, the founder and co-chair of the summit and executive director of the Genetic Policy Institute, which organized the event."It's a big job to do this, and more than just the science," Siegel said, noting that in a growing field now moving beyond basic lab research, the aim is to connect the people who do the work with those who finance it.The three-day summit, which opened Monday in Pasadena, features more than 150 top international speakers and 50 hours of programming with leaders from science, pharmaceutics, business, policy, ethics, law and other fields.The cell therapy industry, a "nascent" field, has emerged to be a potentially multi-billion business with unlimited potential, Siegel said.Stephen Dalton, a University of Georgia professor, reported that one of the biggest developments in stem cell research in the past year was the realization that cells can be transdifferentiated from one state to another without returning to a pluripotent state.Dalton said the principle was previously supported by a few isolated examples but it was not until 2010 that the idea was widely accepted.Mark Sussman, a professor from San Diego State University, called the identification of lung stem cells from human tissue samples capable of regenerating the highly complex and specialized structures of mature lungs a breakthrough in lung biology and regenerative medicine.He said results presented by the Anversa group in the New England Journal of Medicine demonstrate that human lung stem cells can be expanded in vitro and also retain the capacity to integrate into adult tissue upon introduction into mice.The study, Sussman said, has opened up an entirely new field of possibilities for lung regeneration and potential therapeutic applications for many conditions where treatment options are either very limited or nonexistent.

WASHINGTON, Oct. 18 (Xinhua) -- Heart failure (HF) hospitalizations dropped 29.5 percent nationally over the past decade, according to a study by Yale physicians to be published Wednesday in the Journal of the American Medical Association.The risk-adjusted rate of heart failure hospitalization fell from 2,845 to 2,007 per 100,000 person-years from 1998 to 2008 in a fee-for-service Medicare claims analysis by Dr. Jersey Chen of Yale University and colleagues.The team also found that the rate of hospitalization for black men dropped at a lower rate, and that one-year mortality rates declined slightly during that period, but remained high.HF imposes one of the highest disease burdens of any medical condition in the United States and the risk increases with age. As a result, HF ranks as the most frequent cause of hospitalization and re-hospitalization among senior Americans. HF is also one of the most resource-intensive conditions, with direct and indirect costs in the United States estimated at 39.2 billion U.S. dollars in 2010.The study showed that the HF hospitalization rates varied significantly from state to state. The decline in the hospitalization rate from 1998 to 2008 was significantly higher than the national average in 16 states and significantly lower in three states (Wyoming, Rhode Island and Connecticut).Chen and his team also found that risk-adjusted one-year mortality decreased from 31.7 percent to 29.6 percent between 1999 and 2008, a relative decline of 6.6 percent, with substantial variation in different states."Because of the substantial decline in HF hospitalizations, compared to the rate of 1998, there were an estimated 229,000 fewer HF hospitalizations in 2008," said Chen in a statement, adding that with a mean HF hospitalization cost of 18,000 dollars in 2008, this decline represents a savings of 4.1 billion dollars in fee-for-service Medicare."The overall decline in the heart failure hospitalization rate was mainly due to fewer individual patients being hospitalized with heart failure rather than a reduction in the frequency of repeat hospitalizations," said Chen.

WASHINGTON, Dec. 7 (Xinhua) -- The use of two drugs never tried in combination before in ovarian cancer resulted in a 70 percent destruction of cancer cells already resistant to commonly used chemotherapy agents, say researchers at Mayo Clinic in Florida.Their report, published on-line Wednesday in Gynecologic Oncology, suggests that this combination, ixabepilone and sunitinib, might offer a much needed treatment option for women with advanced ovarian cancer.Neither drug is approved for use in ovarian cancer. Ixabepilone is a chemotherapy drug that, like other taxane drugs, targets the microtubules and stops dividing cells from forming a spindle. It has been approved for use in metastatic breast cancer. Sunitinib, approved for use in kidney cancer, belongs to a class of tyrosine kinase inhibitors that stops growth signals from reaching inside cancer cells.When caught at late stages, ovarian cancer is often fatal because it progressively stops responding to the chemotherapy drugs used to treat it."Women die from ovarian cancer because their tumors become resistant to chemotherapy, so a drug that might be able to reduce that resistance -- which may be what this combination of agents is doing -- would be a boon to treatment of this difficult cancer," says study coauthor Gerardo Colon-Otero.The finding also highlights the importance of the role of a molecule, RhoB, that the researchers say is activated by the drug duo. It might be a potential biomarker that may help identify patients who might benefit from such combination therapy, the researchers say.